We receive funding from a variety of sources that recognize the value of our high-impact research.
Supriya Mahajan, PhD, MPH
- Inhibition of Radiation-Induced Coronary Microvascular Disease. Supriya Mahajan (Co-Investigator). NIH. $1,750,000. 9/1/2020-8/1/2025.
- Biomarkers for Type III Hereditary Angioedema. Supriya Mahajan (Co-Investigator). Takeda originally Shire. $275,000. 1/1/2018-12/1/2023.
Jessica Reynolds, PhD
- Pharmacokinetics and Immunodynamics of Immune stimulating chemotherapeutic nanoparticles for TB. Jessica Reynolds (Principal Investigator). NIAID. $2,197,275. 8/1/2018-7/1/2023.
- Initiative for Maximizing Student Development at University at Buffalo. Jessica Reynolds (Co-Investigator). NGMS. 12/1/2021-1/1/2027.
- Sustained release of luzindole. Jessica Reynolds (Co-Principal Investigator). UB. 3/1/2023-1/1/2024.
- Buffalo Clinical and Translational Research Center. Jessica Reynolds (Co-Investigator). NIH. 9/1/2019-1/1/2024.
Stanley Schwartz, MD, PhD
- A Multimodal Hierarchical Theranostic Nanoparticle for Castration Resistant Prostate Cance. Stanley Schwartz (Principal Investigator). Department of Veterans Affairs. 1/1/2022-12/1/2025.